The enigma of gastroesophageal reflux disease among convalescing infants in the NICU: It is time to rethink

Eman F. Badran a, Sudarshan Jadcherla b,*

a Department of Pediatrics, School of Medicine, The University of Jordan, Amman, 11942, Jordan
b Divisions of Neonatology, Pediatric Gastroenterology and Nutrition, Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, 43215, USA

1. Introduction

The global prevalence of GERD in infants is not known and can be variable based on the characteristics of patients, parents, providers, prescribers and prevailing pharmaceutical policies. Hence, the use of tests and therapies can be variable, as well as the consequences in different geographic regions. The lack of uniform care and estimates for infant-GERD diagnosis is largely due to variable definitions, patient heterogeneity and lack of diagnostic criteria to monitor regression or amelioration. Most published studies are based on retrospective observational in origin and high-quality randomized control trials aimed to achieve accuracy with diagnosis and therapies are lacking in infants convalescing in the neonatal intensive care unit (NICU).

Position guidelines [1] and mechanistic studies [2,3] exist for readers to examine the reported condition in detail. In this article, we have alluded the salient aspects of GERD with reference to the convalescing infant in the NICU, although our review has relevance to other pediatric populations as well. Our goals in this article were to 1) clarify definitions and highlight the global prevalence as well as prevailing practices, 2) explain the physiology-pathophysiology of symptoms and GERD diagnosis, 3) explain approaches to diagnosis of GERD, and 4) discuss non-pharmacological approaches and pharmacological approaches, along with their consequences.

1.1. Definition and global prevalence of GERD in infants

Gastroesophageal reflux (GER) involves movement of gastric contents into esophagus and pharynx, and is a common physiologic process in infants, which often resolves with growth and maturation [4]. Regurgitation is a common presentation that occurs daily in 70% of healthy infants and often resolves with maturation by 12–14 months age and changes over childhood [5,6]. When GER events become bothersome if accompanied by other symptoms such as failure to thrive, severe arching and irritability and poor oral feeding or with signs of esophagitis or hematemesis, it is considered as GER disease (GERD) [1,7,8]. Unfortunately, the distinction between GER and GERD definitions have been used rather interchangeably with the consequence of treating many infants in whom the condition is simply physiologic and with time, resolution may happen. Therefore, there is a lack of clarity with true clinical...
Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| GER          | gastroesophageal reflux |
| GERD         | gastroesophageal reflux disease |
| LES          | lower esophageal sphincter |
| UES          | upper esophageal sphincter |
| NICU         | neonatal intensive care unit |

symptoms and therapeutic targets, and physiological and prognostic biomarkers; hence practice variation is very high [9,10]. Scalable accurate methods applicable to the infant with rapidly changing maturational physiology are desperately needed to overcome practice variation.

As a result of uncertainty with the diagnosis of GERD or of its accurate detection, the exact true prevalence is unclear. An estimated GERD diagnosis rates across US NICUs average 10–22% varying widely from 2 to 88% and costing approximately an additional $70,000 US per patient along with an additional month of hospitalization [9,11]. For example, globally, symptom-based prevalence of GERD ranged from an average estimation of: 10.3%–40% in USA [9,12], 22% in Australia [10] and 23.1% in Italy [6]. The exact burden and prevalence from other countries is lacking; understandably so, as the definition remains an enigma in the non-verbal patient. Importantly, it is to be noted that the global variation in GERD diagnosis may be related to parental tolerance of symptoms, accessibility of health care provider, heterogeneity of comorbidities, and changing maturational neuropathology and aerodigestive disease patterns in convalescing infants after ICU care. Regardless, there is a growing concern that GERD is over-diagnosed and over-treated in infants [13]. In fact, the use of acid-suppressive medications in presumed GERD is unacceptably high and has its own consequences in short-term and long-term [11], and a diagnostic label of GERD increases the risk for medication use [14].

1.2. Physiology and pathophysiology of gastro-esophageal junction (GEJ) and basis for symptoms

Excellent articles exist on this topic that are pertinent to the NICU infant [15,16]. The length of foregut is dependent on the size of the infant, and clearly it is smaller in the premature-born than the full-term born neonate, while the feeding volumes are greater of the infant, and clearly it is smaller in the premature-born than NICU infant [15,16]. The length of foregut is dependent on the size (GEJ) and basis for symptoms 1.2. Physiology and pathophysiology of gastro-esophageal junction (GEJ) and basis for symptoms

1.3. Current symptom-based practices to diagnose and manage GERD in infants

Regurgitation can occur as a physiologic phenomenon in the neonate with 2–3 episodes of events per hour [26]. The natural history is that with infant growth and maturation, the symptoms purported to be due to regurgitation or GER resolve and by 6–12 months, these are non-consequential in most cases [4,18]. A parent/provider perception determined 12-symptom based domains have been used to diagnose GERD in infants; this was the Infant-GERD...
Questionnaire-Revised score which was validated for use in infants [8,18], however the validity of which in convalescing NICU infants is yet to be proven. In fact, the Rome criteria considered to evaluate the prevalence of regurgitation in healthy infant at checkups visit to differentiate clinically meaningful change from clinically non-significant change by choosing the IGERQR score [6]. The scores in NICU infants run the risk of provider bias as the same providers are not always present to score. Importantly, owing to the heterogeneity of disease in the NICU infant, the combination of developing maturational-neurological-aerodigestive-and gastrointestinal symptoms can all be erroneously attributed to GERD symptoms or signs, and thus symptom-based scores alone are less reliable.

1.4. Evidence-guided approach to diagnosis and management of GERD in infants [3,25,27–29]

Majority of healthy preterm and full-term infants regurgitate, and continue to feed, gain weight and do not have worsening respiratory illness. Parental and allied-health care provider reassurance, growth and dietary evaluation and counselling, and follow up is all that is required. Therapeutic interventions should be considered if complications ensue in the presence of GER. The purpose of diagnostic testing is to determine whether GER is contributing to symptoms and disease state and to help with predicting treatment success. Diagnostic approach and therapeutic intervention should be limited to high-risk infants. Various testing modalities have been used to evaluate GERD and unfortunately, no single test provides a definite diagnosis.

Risk factors for GERD in the NICU setting: Infants at-risk may include those born with congenital craniofacial and upper gastrointestinal anomalies, infants with growth failure, perinatal neurological illness, airway-, pulmonary- and digestive pathologies. Such infants require careful evaluation. GERD may be the contributing factor and needs to be ruled out in those high-risk infants who have recurrent vomiting or regurgitation, excessive crying and irritability, difficulty feeding, worsening pulmonary disease and failure to thrive. Persistence of troublesome symptoms in presence of chronic GER constitutes GERD. These symptoms may include excessive regurgitation, recurrent aspiration leading to airway hyperreactivity, and other pulmonary complications, neurobehavioral manifestations such as excessive arching, irritability and Sandifer syndrome. Excessive regurgitation can lead to persistent stimulation of upper aerodigestive tract leading to cough, sneezing and cardio-respiratory changes like bradycardia and desaturations.

Another important clue to GER may be symptom of dysphagia. Lack of swallowing can cause nasal regurgitation, hoarse cry, choking and stridor if there is anterograde aspiration during swallowing of a bolus.

Survey for anomalies in infants-at risk for GERD: It is important to rule out foregut malformations before instituting functional studies. Upper Gastrointestinal fluoroscopy contrast study is recommended whenever anatomical malformation of foregut is suspected. Additional fluoroscopic studies like video fluoroscopic swallow study and esophageal fluoroscopy are also used to evaluate sucking and swallowing function along with anatomical defects. It is to be noted that radiological studies are not diagnostic for GERD, but rather provide clues to structural abnormalities if any. Specific to those include upper esophageal sphincter and lower esophageal sphincter abnormalities (achalasia), hiatal hernia, diaphragmatic defects, tracheo-esophageal fistula, pyloric stenosis, gastroparesis, gastrochisis and omphalocele, malrotation, duodenal and intestinal webs, intestinal duplications, and esophageal and intestinal strictures.

Pathophysiological mechanism behind GERD and the role of pH-impedance studies: are based on physical (solid, liquid, gas or mixed) and chemical (acid, weakly acid, nonacid, alkaline) compositions of refluxate. milk constituent variability and proximal esophageal extent. Concurrent pH monitoring with multichannel intraluminal impedance studies is currently the gold standard to

Fig. 2. Characterization of GER events during pH-impedance. 24-hr pH-impedance characterizes physical-chemical (liquid/gas/mixed, acid/non-acid) and spatial-temporal (height, clearance times).

GER characteristics and symptom correlation. Potential examples are: A) liquid acid characterized by retrograde drop in impedance and pH drop below 4. Note this is not full-column GER (does not reach Z1). Bolus clearance time (BCT) determines bolus contact and clearance efficiency. B) Gas non-acid characterized by rapid rise in impedance reaching the most proximal impedance channel (Z1) and pH > 4. Crying is associated with this GER event. C) Mixed acid characterized by liquid and gas components with pH < 4. Acid clearance time (ACT) measures esophageal acid contact time. As numerous iterations are possible, it is important to discern the true cause of symptoms for effective diagnosis and therapies.
To the high risk for life-threatening events and sudden deaths, prone position decreases GER events, it is not recommended owing to the lack of evidence. Reflux events are not evidence-based and are based on retrospective observations. The transpyloric method may be a short-term bridge for selected tube feedings, but it is rarely needed unless strong clinical indication exists. Further systematic studies are necessary. GERD has a high risk for short-term and long-term effects. Method of feeding may alter GERD severity, and has heterogeneity with symptom presentation along with co-existing morbidities.

1.5. Treatment strategies for GERD in the NICU setting

The therapy depends on the specific cause and correction of contributing factors. The above-mentioned diagnostic approaches will give us clues to pursuing expectant surveillance, medical, or surgical approaches. Supine position is the best position for optimal airway safety. Pharmacological therapy to suppress gastric acidity is all that is necessary as GER or GERD related causal and ameliorating factors will improve over time.

Non-pharmacologic therapies: It is important to recognize and minimize GERD provoking factors such as frequent suctioning, frequent feeding tube manipulation, and frequent chest physical therapy. Attention to airway symptoms and lung disease will help. Efforts to minimize coughing and wheezing episodes in those with chronic lung disease will be advisable. Safe-sleeping positions and supine position is protective in infants as airway protective mechanisms are well maintained in such situations [27,29,32]. Although prone position decreases GER events, it is not recommended owing to the high risk for life-threatening events and sudden deaths owing to airway closure [1,33].

Feeding strategies: Prevailing feeding strategies are very wide and are not evidence-based and are based on retrospective observations [34,37]. Cow's milk allergy is shown to cause indistinguishable GERD like symptoms in the full-term infant. Therefore, considering a hydrolyzed formula for 1–2 weeks may treat reflux type of manifestations. Human milk has better gastric emptying time and should always be encouraged. There is evidence that human milk has fewer GER episodes and breast-fed infants have less esophageal acid exposure than formula fed infants [35,36,38]. Increasing calories concentration and thickening the feed with added starch (rice cereal, sodium alginate, corn starch) can reduce regurgitation and GER events however such approaches have not been studies longitudinally and systemically in preterm and term infants for long-term effects. Method of feeding may alter GERD frequency in selected patients where other nonpharmacological approaches are ineffective. Continuous drip feeds via intragastric or transpyloric method may be a short-term bridge for selected tube dependent infants to prevent growth failure. All these approaches have not been rigorously tested and systematically studied in convalescing NICU infants.

Pharmacologic therapy: There is no good pharmacological agent recommended for GERD in the NICU setting. Despite lack of benefit, there is a high prevalence of GERD medication administration in both inpatient and outpatient setting, and systematic data is lacking to support efficacy of these medications. These include acid-suppressive agents including Histamine 2 receptor antagonists (H2RA) and proton pump inhibitors (PPI) that are used commonly. Both these agents have a high risk for short-term and long-term side effects [39–41]. Besides causing profound acid suppression, other side effects include small bowel bacteria overgrowth, infections, bowel inflammation and necrotizing enterocolitis, malabsorption of nutrients, decreased absorption of calcium and altered digestion, diarrhea and vomiting, in addition to osteopenia and bone fractures. Acid suppressive agents should not be used unless there is a strong objective-evidence based indication. Prokinetics such as Erythromycin may improve gastroduodenal motility in preterm infant older than 33 weeks PMA improving gastric emptying but has no effect on GER events. However, it has been associated with higher incidence of hypertrophic pyloric stenosis.

Surgical Therapy: Indications for anti-reflux surgery include those with anomalies, failure of both medical and behavioral therapies and if GERD related supra-esophageal and extra-esophageal complications should arise. However, accuracy with diagnosis, anatomical and functional integrity studies of gastro-esophageal junction need to be undertaken prior to surgical procedures, whenever possible. Any surgical procedure carries a risk of anesthesia, surgery and post-surgical complications. Adverse complications of fundoplication include bloating, GER recurrence due to wrap breakdown and small bowel obstruction, in addition to anterograde aspiration that may occur during swallowing.

2. Summary

Management approaches of infant GERD are summarized in Table 1. GER and GERD in convalescing infants are sometimes indistinguishable clinically, and clinical diagnostic criteria are lacking for precision and reproducibility. Evaluation of dietetic history, anomalies, instrumentation and diagnosis based on symptom-correlation may be necessary in the NICU infant setting. Expectant management with better quality nutrition and feeding management strategies while monitoring for growth and development are helpful. Supine position is the best position for optimal airway safety. Pharmacological therapy to suppress gastric acidity must be limited and weighed with caution. Surgical therapies are rarely needed unless strong clinical indication exists. Further systematic research is needed to develop generalizable guidelines for the care of convalescing NICU infant who is of a different phenotype and has heterogeneity with symptom presentation along with co-existing morbidities.

Table 1

| Key highlights |
|----------------|
| The complexity in the convalescing infant in the NICU need careful consideration prior to GERD diagnosis. |
| Pathophysiological basis for symptoms commonly ascribed to reflux can be multifactorial and not always associated with GER or GERD. |
| The severity of acidity, frequency of non-acid events, proximal extent of the refluxate and infant's sensitivity to respond to esophageal provocation and presence of adaptive reflexes determine the pathophysiological basis for GERD. |
| Risk factors for developing GERD presence and severity need to be considered before attributing GERD diagnosis. |
| Medical or surgical treatment should not be based solely on clinical signs or parental/provider perceptions. |
| The label of GERD diagnosis even in healthy infants increases the interest in using prescribed or non-prescribed medications. |
| The consequences of acid-suppressive medications to manage presumed GERD are severe and have long-term repercussions. |
Acknowledgment

We are grateful to Ms. Zakia Sultana, BA, for helping with art work, references, and with manuscript submission process.

References

[1] Rosen R, Vandenplas Y, Singendonk M, Cabana M, Di Lorenzo C, Gottrand F, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for pediatric gastroenterology, hepatology, and nutrition and the European Society for pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr 2018;66(3):516–54.

[2] Omari TI, Barnett C, Snel A, Goldsworthy W, Haslam R, Davidson G, et al. Mechanisms of gastroesophageal reflux in healthy premature infants. J Pediatr 1998;133(5):650–4.

[3] Gulati IK, Jadcherla SR. Gastroesophageal reflux disease in the neonatal intensive care unit infant: who needs to be treated and what approach is beneficial? Pediatr Clin North Am 2019;66(2):461–73.

[4] Nelson SP, Chen EH, Sinaee GM, Christoffel KG. Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997;151(6):569–72.

[5] Hegar B, Devanti NR, Kadam M, Alatas S, Firmansyah A, Vandenplas Y. Natural evolution of regurgitation in healthy infants. Acta Paediatr 2009;58(7):1189–93.

[6] Campanozzi A, Boccia G, Pensabene L, Panetta F, Marseglia A, Strisciuglio P, et al. Prevalence and natural history of gastroesophageal reflux: pediatric prospective survey. Pediatrics 2009;123(3):779–83.

[7] Hegar B, Boediarso A, Firmansyah A, Vandenplas Y. Investigation of regurgitation and other symptoms of gastroesophageal reflux in Indonesian infants. World J Gastroenterol 2004;10(12):1795–7.

[8] Orenstein SR. Symptoms and reflux in infants: infant gastroesophageal reflux questionnaire revised (I-GERQ-R)—utility for symptom tracking and diagnosis.Curr Gastroenterol Rep 2010;12(6):431–6.

[9] Jadcherla SR, Slaughter JL, Stenger MR, Kleinhoff M, Kelleher K, Gardner W. Practice variance, prevalence, and economic burden of premature infants diagnosed with GERD. Hosp Pediatr 2013;3(4):335–41.

[10] Bell JC, Schneider FJ, Harrison C, Trevena L, Hosick H, Elshag AG, et al. Acid suppressants for managing gastro-oesophageal reflux and gastro-oesophageal reflux disease in infants: a national survey. Arch Dis Child 2018;103(7):660–4.

[11] Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States Children's Hospitals. J Pediatr 2016;174:63–70 e3.

[12] Robin SG, Keller C, Zwiener R, Hyman PE, Nurko S, Saps M, et al. Prevalence of acid suppressant therapy exposure and fracture in young children. Pediatrics 2019

[13] Hassall E. Over-prescription of acid-suppressing medications in infants: how it came about, why it’s wrong, and what to do about it. J Pediatr 2012;160(2):159–62.

[14] Scherer LD, Zimkund-Fisher BJ, Fagerlin A, Tarini BA. Influence of “GERD” label on parents' decision to medicate infants. Pediatrics 2013;131(5):839–45.

[15] Gulati IK, Jadcherla SR. Gastroesophageal reflux disease in the neonatal intensive care unit infant who needs to Be treated and what approach is beneficial? Pediatr Clin N Am 2019;66(2):461–7.

[16] Jadcherla SR. Pathophysiology of aerodigestive pulmonary disorders in the neonate. Clin Perinatol 2012;39(3):639–54.

[17] Gupta A, Jadcherla SR. The relationship between somatic growth and in vivo gastroesophageal segmental and sphincteric growth in human neonates. J Pediatr Gastroenterol Nutr 2006;43(1):35–41.

[18] Orenstein SR, Shalaby TM, Cohn JP. Reflux symptoms in 100 normal infants: diagnostic validity of the infant gastroesophageal reflux questionnaire. Clin Pediatr (Phila) 1996;35(12):607–14.

[19] Sivarao DV, Goyal RK. Functional anatomy and physiology of the upper esophageal sphincter. Am J Med 2000;108(Suppl 4a):275–375.

[20] Goyal RK, Padmanabhan R, Sang Q. Neural circuits in swallowing and abdominal vagal afferent-mediated lower esophageal sphincter relaxation. Am J Med 2001;111(Suppl):955–1055.

[21] Rattan S, Goyal RK. Neural control of the lower esophageal sphincter: influence of the vagus nerves. J Clin Invest 1974;54(4):899–906.

[22] Omari TI, Mili K, Davidson G, Fraser R, Haslam R, Goldsworthy W, et al. Characterisation of relaxation of the lower oesophageal sphincter in healthy premature infants. Gut 1997;40(3):370–5.

[23] Kawahara H, Dent J, Davidson G. Mechanisms responsible for gastroesophageal reflux in children. Gastroenterology 1997;113(2):399–408.

[24] Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology 1995;109(2):601–10.

[25] Collins CR, Hasenstab KA, Nawaz S, Jadcherla SR. Mechanisms of aerodigestive symptoms in infants with varying acid reflux index determined by esophageal manometry. J Pediatr 2019;206:240–7.

[26] Lopez-Alonso M, Moya MJ, Cabo JA, Ribas J, del Carmen Macias M, Silny J, et al. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux. Pediatrics 2006;118(2):e299–308.

[27] Sivalingam M, Sitaram S, Hasenstab KA, Wei L, Woodley FW, Jadcherla SR. Effects of esophageal acidification on troublesome symptoms: an approach to characterize true acid GERD in dysphagic neonates. Dysphagia 2017;32(4):509–19.

[28] Jadcherla SR, Peng J, Chan CY, Moore R, Wei L, Fernandez S, et al. Significance of gastroesophageal reflux in relation to physical, chemical, and spatio-temporal characteristics in symptomatic intensive care unit infants. Pediatr Res 2011;70(2):192–8.

[29] Qureshi A, Malik M, Spielberg M, Khuhro A, Jadcherla S. The role of sleep in the modulation of gastroesophageal reflux and symptoms in NICU neonates. Pediatr Neurol 2015;53(3):226–32.

[30] Vandenplas Y, Rudolph CD, Di Lorenzo C, Hassall E, Liptak G, Mazur L, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for pediatric gastroenterology, hepatology, and nutrition (NASPGHAN) and the European Society for pediatric gastroenterology, hepatology, and nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr 2009;49(4):498–547.

[31] Vandenplas Y, Goyaerts H, Helven S, Racre L. Gastroesophageal reflux, as measured by 24-hour Ph monitoring, in 509 healthy infants screened for risk of sudden-infant-death-syndrome. Pediatrics 1991;88(4):834–40.

[32] Ammiri M, Djeddi D, Leke A, Delaunay S, Stephan-Blanchard E, Bach V, et al. Relationship between sleep and acid gastro-oesophageal reflux in neonates. J Sleep Res 2012;21(1):80–6.

[33] Lang IM, Medda BK, Shaker R, Jadcherla S. The effect of body position on esophageal reflexes in cats: a possible mechanism of SIDS? Pediatr Res 2018;83(3):731–8.

[34] Infante Pina D, Batia Llach X, Arino-Armengol B, Villegas Iglesias V. Prevalence and dietetic management of mild gastrointestinal disorders in milk-fed infants. World J Gastroenterol 2008;14(2):248–54.

[35] Chen PL, Soto-Ramirez N, Zhang HM, Karmaus W. Association between infant feeding modes and gastroesophageal reflux disease in children-Basel 2016;3(4).

[36] Heacock HJ, Jeffery HE, Baker JL, Page M. Influence of breast versus formula milk on physiological gastroesophageal reflux in healthy, newborn infants. J Pediatr Gastroenterol Nutr 1992;14(1):41–6.

[37] El-Mahdy MA, Mansoor FA, Jadcherla SR. Pharmacological management of gastroesophageal reflux disease in infants: current opinions. Curr Opin Pharmacol 2017;37:112–7.

[38] Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. Pediatrics 2019 Jul;144(1). https://doi.org/10.1542/peds.2018-2625. pii: e20182625, Epub 2019 Jun 7.

[39] Omari T, Davidson G, Bondarov P, Nauchler E, Nilsson C, Lundborg P. Pharmacokinetics and acid-suppressive effects of esomeprazole in infants 1–24 Months old with symptoms of gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2015;60(Suppl 1):S2–8.